GSK wins yet an­oth­er re­prieve for block­buster Ad­vair fran­chise as My­lan is hit (again) with a CRL

Glax­o­SmithK­line CEO Em­ma Walm­s­ley is work­ing on re­build­ing the phar­ma gi­ant’s R&D op­er­a­tion with some of the best minds in the busi­ness. But in the mean­time, she can re­ly on re­peat­ed set­backs among her ri­vals to win some bad­ly need­ed breath­ing room.

Case in point: Wednes­day evening My­lan re­port­ed that the FDA had kicked back its copy­cat ver­sion of Ad­vair, again. This fol­lows a whole slate of re­jec­tions for com­pa­nies look­ing to grab the mega-block­buster fran­chise away with cheap­er copies of the res­pi­ra­to­ry drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER